Weight-loss drugs may ease chronic migraines, early study suggests

An analysis of about 11,000 people with chronic migraine found that those taking GLP-1 drugs had lower rates of emergency room visits and hospitalizations compared with patients on topiramate, though researchers say the findings are preliminary and show an association rather than causation.

A preliminary study examined whether GLP-1 weight-loss medications are linked to changes in outcomes for people with chronic migraine. Researchers analyzed data from roughly 11,000 patients who meet the clinical definition of chronic migraine. The study compared outcomes for patients prescribed GLP-1 drugs with those prescribed topiramate. The findings are being shared in advance of presentation at the American Academy of Neurology's annual meeting in April. Key findings: - The analysis included about 11,000 people with chronic migraine. - Patients taking GLP-1 drugs were reported to be 10% less likely than those taking topiramate to have a migraine-related emergency room visit. - Those on GLP-1 medications were 14% less likely to be hospitalized for any reason in the study's comparison. - Patients on GLP-1 drugs were less likely to start an additional preventive migraine medication than those on topiramate. - Study authors emphasized the results show an association and described the findings as preliminary. Summary: The study suggests an association between GLP-1 drug use and lower use of emergency care and hospitalizations among people with chronic migraine, but it does not establish causation. Researchers noted possible anti-inflammatory and neurovascular mechanisms are under early investigation, and they characterize the results as preliminary pending further research and presentation at the professional meeting in April.